223 related articles for article (PubMed ID: 11774252)
1. Pegylated liposomal tumor necrosis factor-alpha results in reduced toxicity and synergistic antitumor activity after systemic administration in combination with liposomal doxorubicin (Doxil) in soft tissue sarcoma-bearing rats.
ten Hagen TL; Seynhaeve AL; van Tiel ST; Ruiter DJ; Eggermont AM
Int J Cancer; 2002 Jan; 97(1):115-20. PubMed ID: 11774252
[TBL] [Abstract][Full Text] [Related]
2. Low-dose tumor necrosis factor-alpha augments antitumor activity of stealth liposomal doxorubicin (DOXIL) in soft tissue sarcoma-bearing rats.
Ten Hagen TL; Van Der Veen AH; Nooijen PT; Van Tiel ST; Seynhaeve AL; Eggermont AM
Int J Cancer; 2000 Sep; 87(6):829-37. PubMed ID: 10956394
[TBL] [Abstract][Full Text] [Related]
3. Addition of low-dose tumor necrosis factor-alpha to systemic treatment with STEALTH liposomal doxorubicin (Doxil) improved anti-tumor activity in osteosarcoma-bearing rats.
Hoving S; Seynhaeve AL; van Tiel ST; Eggermont AM; ten Hagen TL
Anticancer Drugs; 2005 Jul; 16(6):667-74. PubMed ID: 15930896
[TBL] [Abstract][Full Text] [Related]
4. Effect of low-dose tumor necrosis factor-alpha in combination with STEALTH liposomal cisplatin (SPI-077) on soft-tissue- and osteosarcoma-bearing rats.
Hoving S; van Tiel ST; Eggermont AM; ten Hagen TL
Anticancer Res; 2005; 25(2A):743-50. PubMed ID: 15868905
[TBL] [Abstract][Full Text] [Related]
5. Synergistic antitumor response of interleukin 2 with melphalan in isolated limb perfusion in soft tissue sarcoma-bearing rats.
Hoving S; Brunstein F; aan de Wiel-Ambagtsheer G; van Tiel ST; de Boeck G; de Bruijn EA; Eggermont AM; ten Hagen TL
Cancer Res; 2005 May; 65(10):4300-8. PubMed ID: 15899822
[TBL] [Abstract][Full Text] [Related]
6. Tumor necrosis factor-alpha augmented tumor response in B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (Doxil) correlates with altered Doxil pharmacokinetics.
Brouckaert P; Takahashi N; van Tiel ST; Hostens J; Eggermont AM; Seynhaeve AL; Fiers W; ten Hagen TL
Int J Cancer; 2004 Apr; 109(3):442-8. PubMed ID: 14961585
[TBL] [Abstract][Full Text] [Related]
7. Biodistribution and tumor localization of stealth liposomal tumor necrosis factor-alpha in soft tissue sarcoma bearing rats.
van der Veen AH; Eggermont AM; Seynhaeve AL; van Tiel ; ten Hagen TL
Int J Cancer; 1998 Sep; 77(6):901-6. PubMed ID: 9714061
[TBL] [Abstract][Full Text] [Related]
8. Isolated limb perfusion with actinomycin D and TNF-alpha results in improved tumour response in soft-tissue sarcoma-bearing rats but is accompanied by severe local toxicity.
Seynhaeve AL; de Wilt JH; van Tiel ST; Eggermont AM; ten Hagen TL
Br J Cancer; 2002 Apr; 86(7):1174-9. PubMed ID: 11953868
[TBL] [Abstract][Full Text] [Related]
9. Liposomal doxorubicin with and without TNFalpha in the perfusional treatment of advanced soft tissue limb sarcoma: preliminary results.
Di Filippo F; Anzà M; Garinei R; Cavaliere F; Perri P; Botti C; Di Angelo P; Di Filippo S; Maini CL; Pasqualoni R; Di Segni S; Colantonio S; Bruno P; Piarulli L; Principi F
In Vivo; 2006; 20(6A):735-8. PubMed ID: 17203757
[TBL] [Abstract][Full Text] [Related]
10. Synergistic antitumour effect of TNF-SAM2 with melphalan and doxorubicin in isolated limb perfusion in rats.
de Wilt JH; Soma G; ten Hagen TL; Kanou J; Takagi K; Nooijen PT; Seynhaevel AL; Eggermont AM
Anticancer Res; 2000; 20(5B):3491-6. PubMed ID: 11131652
[TBL] [Abstract][Full Text] [Related]
11. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy.
Gabizon AA
Cancer Invest; 2001; 19(4):424-36. PubMed ID: 11405181
[TBL] [Abstract][Full Text] [Related]
12. Increased TIA-1 gene expression in the tumor microenvironment after locoregional administration of tumor necrosis factor-alpha to patients with soft tissue limb sarcoma.
Mocellin S; Provenzano M; Lise M; Nitti D; Rossi CR
Int J Cancer; 2003 Nov; 107(2):317-22. PubMed ID: 12949814
[TBL] [Abstract][Full Text] [Related]
13. Combination radiofrequency ablation with intratumoral liposomal doxorubicin: effect on drug accumulation and coagulation in multiple tissues and tumor types in animals.
Ahmed M; Liu Z; Lukyanov AN; Signoretti S; Horkan C; Monsky WL; Torchilin VP; Goldberg SN
Radiology; 2005 May; 235(2):469-77. PubMed ID: 15858089
[TBL] [Abstract][Full Text] [Related]
14. Toxicity and antitumor activity of interferon gamma alone and in combinations with TNFalpha and melphalan in isolated limb perfusion in the BN175 sarcoma tumor model in rats.
Manusama ER; De Wilt JH; Ten Hagen TL; Marquet RL; Eggermont AM
Oncol Rep; 1999; 6(1):173-7. PubMed ID: 9864423
[TBL] [Abstract][Full Text] [Related]
15. Expression of P-glycoprotein, multidrug resistance-associated protein 1, and lung resistance-related protein in human soft tissue sarcomas before and after hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan.
Komdeur R; Plaat BE; Hoekstra HJ; Molenaar WM; Hollema H; van den Berg E; Mastik MF; van der Graaf WT
Cancer; 2001 May; 91(10):1940-8. PubMed ID: 11346877
[TBL] [Abstract][Full Text] [Related]
16. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).
Toma S; Tucci A; Villani G; Carteni G; Spadini N; Palumbo R
Anticancer Res; 2000; 20(1B):485-91. PubMed ID: 10769710
[TBL] [Abstract][Full Text] [Related]
17. Treatment modifications in tumour necrosis factor-α (TNF)-based isolated limb perfusion in patients with advanced extremity soft tissue sarcomas.
Deroose JP; Grünhagen DJ; de Wilt JH; Eggermont AM; Verhoef C
Eur J Cancer; 2015 Feb; 51(3):367-73. PubMed ID: 25529370
[TBL] [Abstract][Full Text] [Related]
18. Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models.
Gabizon A; Tzemach D; Mak L; Bronstein M; Horowitz AT
J Drug Target; 2002 Nov; 10(7):539-48. PubMed ID: 12683721
[TBL] [Abstract][Full Text] [Related]
19. Doxorubicin in isolation limb perfusion in the treatment of advanced limb soft tissue sarcoma.
Di Filippo F; Garinei R; Anzà M; Cavaliere F; Giannarelli D; Cagol PP; Rossi CR; Santinami M; Deraco M; Botti C; Perri P; Di Filippo S; Piarulli L; Bruno P
J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):81-7. PubMed ID: 16767912
[TBL] [Abstract][Full Text] [Related]
20. Hyperthermic isolated limb perfusion in locally advanced limb soft tissue sarcoma: A 24-year single-centre experience.
Rastrelli M; Campana LG; Valpione S; Tropea S; Zanon A; Rossi CR
Int J Hyperthermia; 2016; 32(2):165-72. PubMed ID: 26608883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
